Our R&D programmes focus on development of prognostic and predictive glycomic blood biomarkers and Immunofrailty Model. These innovations will enable early detection and treatment personalisation for Inflammatory conditions in clinical practice.

Our Immunofrailty blood test is a measure of the fitness of your immune system.

Prognostic and predictive biomarker to support clinical decision-making in Inflammatory Bowel Disease

This Biomarker has been developed to identify immunofrail individuals likely to suffer serious inflammatory episodes if they were to be infected with SARS-Cov-2 virus.